Michel Ducreux

Hepatology · 2000–2021

A researcher in the Science corpus: 15 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Michel Ducreux trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Llovet
  2. Jordi Bruix1 , 2
  3. Riccardo Lencioni

Papers from Michel Ducreux's perspective

Ordered by how strongly the researchers Michel Ducreux trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  3. Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
  4. Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
  5. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
  6. The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
  7. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (Journal of Clinical Oncology)
  8. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (Journal of Hepatology)
  9. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. (Journal of the American College of Surgeons)
  10. Noninvasive assessment of liver fibrosis (Hepatology)

Their papers